[1]邵长水,李 峰.沙丁胺醇联合盐酸氨溴索治疗慢性阻塞性肺疾病的疗效及对肺功能指标的影响[J].医学信息,2024,37(16):100-103.[doi:10.3969/j.issn.1006-1959.2024.16.022]
　SHAO Chang-shui,LI Feng.Efficacy of Salbutamol Combined with Ambroxol Hydrochloride in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on Pulmonary Function Indexes[J].Journal of Medical Information,2024,37(16):100-103.[doi:10.3969/j.issn.1006-1959.2024.16.022]
点击复制

沙丁胺醇联合盐酸氨溴索治疗慢性阻塞性肺疾病的疗效及对肺功能指标的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年16期
页码:
100-103
栏目:
论著
出版日期:
2024-08-15

文章信息/Info

Title:
Efficacy of Salbutamol Combined with Ambroxol Hydrochloride in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on Pulmonary Function Indexes
文章编号:
1006-1959（2024）16-0100-04
作者:
邵长水1; 李 峰2
1.横峰县妇幼保健院内科，江西 横峰 334300；2.横峰县人民医院内科，江西 横峰 334300
Author(s):
SHAO Chang-shui1; LI Feng2
1.Department of Internal Medicine,Hengfeng County Maternal and Child Health Hospital,Hengfeng 334300,Jiangxi,China;2.Department of Internal Medicine,Hengfeng County People’s Hospital,Hengfeng 334300,Jiangxi,China
关键词:
慢性阻塞性肺疾病; 沙丁胺醇; 盐酸氨溴索; 肺功能; 炎症指标
Keywords:
Chronic obstructive pulmonary disease; Salbutamol; Ambroxol hydrochloride; Lung function; Inflammatory indexes
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2024.16.022
文献标志码:
A
摘要:
目的 研究沙丁胺醇联合盐酸氨溴索治疗慢性阻塞性肺疾病（COPD）的临床疗效及对患者肺功能指标的影响。方法 以2020年6月-2023年6月横峰县妇幼保健院收治的62例COPD患者为研究对象，经随机数字表法分为对照组与观察组，各31例。两组均给予常规治疗，在此基础上，对照组应用沙丁胺醇治疗，观察组则采用沙丁胺醇联合盐酸氨溴索治疗，比较两组临床疗效、肺功能[用力肺活量（FVC）、1秒钟用力呼气容积（FEV1）、1秒率（FEV1/FVC）]、症状缓解时间（咳嗽、咳痰、胸闷气短）、炎症指标[C反应蛋白（CRP）、白细胞介素-6（IL-6）]、不良反应。结果 观察组治疗总有效率为96.77%，高于对照组的83.87%（P＜0.05）；两组治疗后FVC、FEV1、FEV1/FVC指标高于治疗前，且观察组FVC、FEV1、FEV1/FVC高于对照组（P＜0.05）；观察组症状缓解时间（咳嗽、咳痰、呼吸困难）短于对照组（P＜0.05）；两组治疗后CRP、IL-6水平低于治疗前，且观察组CRP、IL-6水平低于对照组（P＜0.05）；观察组与对照组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 沙丁胺醇联合盐酸氨溴索治疗COPD的效果肯定，可改善患者肺功能，加速症状缓解，下调炎症指标，且具有较高用药安全性。
Abstract:
Objective To study the clinical efficacy of salbutamol combined with ambroxol hydrochloride in the treatment of chronic obstructive pulmonary disease (COPD) and its effect on pulmonary function indexes.Methods From June 2020 to June 2023, 62 patients with COPD admitted to the Hengfeng County Maternal and Child Health Hospital were divided into control group and observation group by random number table method, with 31 patients in each group. Both groups were given conventional treatment. On this basis, the control group was treated with salbutamol, while the observation group was treated with salbutamol combined with ambroxol hydrochloride. The clinical efficacy, pulmonary function [forced vital capacity (FVC), forced expiratory volume in one second (FEV1), one-second rate (FEV1/FVC)], symptom relief time (cough, sputum, chest tightness and shortness of breath), inflammatory indexes[C-reactive protein (CRP), interleukin-6 (IL-6)] and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.77%, which was higher than 83.87% in the control group (P<0.05). After treatment, the indexes of FVC, FEV1 and FEV1/FVC in the two groups were higher than those before treatment, and the indexes in the observation group were higher than those in the control group (P<0.05). The symptoms relief time (cough, expectoration, dyspnea) in the observation group were shorter than those in the control group (P<0.05). After treatment, the levels of CRP and IL-6 in the two groups were lower than those before treatment, and the levels of CRP and IL-6 in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).Conclusion Salbutamol combined with ambroxol hydrochloride is effective in the treatment of COPD, which can improve lung function, accelerate symptom relief, down-regulate inflammatory indicators, and has high drug safety.

参考文献/References:

[1]白龙,姬妍娜,刘改娥.无创机械通气联合沙丁胺醇雾化吸入对老年COPD患者氧代谢、肺功能及血气指标的影响[J].海南医学,2022,33(16):2068-2071.[2]陈宇清,王铭杰,朱东,等.稳定期Ⅱ、Ⅲ级慢性阻塞性肺疾病患者的气道阻力对呼出气流受限的影响分析[J].诊断学理论与实践,2019,18(4):418-422.[3]张秀珠,王树录.布地奈德、沙丁胺醇、异丙托溴铵治疗慢阻肺急性加重期的疗效及对通气功能、凝血指标的影响[J].血栓与止血学,2022,28(3):721-723.[4]王婷,李海明,夏于新,等.慢阻肺急性发作患者应用无创机械通气联合沙丁胺醇雾化吸入对机体氧代谢、胸肺顺应性及呼吸动力学的影响观察[J].湖南师范大学学报(医学版),2021,18(6):121-124.[5]陈洁姗,邢可.盐酸氨溴索辅助治疗老年慢性阻塞性肺疾病的临床疗效观察[J].中国病案,2019,20(5):64-67.[6]蔡海彬,刘国雄,谢坚,等.盐酸氨溴索治疗慢性阻塞性肺疾病合并肺部感染的疗效观察[J].西北药学杂志,2018,33(1):113-116.[7]黄露,杨栋,李风波,等.厄多司坦联合沙丁胺醇治疗慢性阻塞性肺疾病的疗效及对血清因子的影响[J].现代药物与临床,2021,36(3):479-483.[8]李静,刘红梅,肖文香.糖皮质激素联合沙丁胺醇雾化吸入对慢阻肺急性加重期患者的疗效及肺功能、炎症因子的影响[J].海南医学,2021,32(16):2062-2065.[9]万东武,陈祥,詹茂芹,等.布地奈德、盐酸氨溴索和沙丁胺醇三联治疗COPD急性加重期患者的临床观察[J].临床和实验医学杂志,2020(22):2404-2407.[10]何淑霞,俞峭拔,孙小丽,等.硫酸沙丁胺醇联合噻托溴铵治疗慢性阻塞性肺疾病急性加重期患者的临床研究[J].中国临床药理学杂志,2020,36(12):1606-1609.[11]李芳,程玉峰,吴成明,等.沙丁胺醇联合二羟丙茶碱治疗慢性阻塞性肺疾病急性加重期的临床研究[J].现代药物与临床,2020,35(6):1171-1175.[12]陈亮,龚勇,吴旭.硫酸沙丁胺醇联合不同剂量布地奈德混悬液雾化吸入治疗慢性阻塞性肺疾病急性加重期的临床观察[J].实用医院临床杂志,2020,17(3):151-154.[13]杨振英,王亚坤,周礼清,等.糖皮质激素类联合肾上腺素能β激动剂对慢性阻塞性肺疾病急性加重期患者的疗效分析[J].安徽医药,2018,22(1):151-155.[14]周少珠,叶旭军,杨静,等.沙丁胺醇、布地奈德不同雾化吸入联合头孢哌酮钠舒巴坦钠对AECOPD患者血气指标和肺功能的影响[J].现代生物医学进展,2020,20(8):1468-1472.[15]董元元,樊恭春,熊艳林,等.沙丁胺醇联合福多司坦治疗慢性阻塞性肺疾病稳定期的疗效及对患者血清IL-6、TNF-α、hs-CRP水平的影响[J].现代生物医学进展,2019,19(17):3389-3392.[16]汪娟,靳攀.沙丁胺醇气雾剂联合羧甲司坦片治疗AECOPD患者的临床效果[J].湖南师范大学学报(医学版),2022,19(3):13-16.[17]才让吉,包八月,才让卓玛,等.乙酰半胱氨酸泡腾片联合硫酸沙丁胺醇气雾剂对COPD患者稳定期肺功能及血清可溶性髓样细胞触发受体-1的影响[J].河北医学,2019,25(5):716-722.[18]孔繁华,宋玉勤,张天涛,等.硫酸沙丁胺醇联合噻托溴铵对慢性阻塞性肺疾病(COPD)急性加重期患者脑钠肽(BNP)、前白蛋白(PA)水平的影响[J].药物生物技术,2021,28(6):615-618.[19]张军战.异丙托溴铵联合布地奈德及沙丁胺醇治疗慢性阻塞性肺疾病急性加重期的临床疗效及安全性[J].实用临床医药杂志,2019,23(3):57-59.[20]李艳艳.纳洛酮联合沙丁胺醇对COPD合并呼吸衰竭患者IL-6、TNF-α和IL-8的影响[J].河北医药,2018,40(7):1068-1070.[21]张龙,许伟,黄崇健.沙丁胺醇与噻托溴铵联合治疗对慢性阻塞性肺疾病急性加重期患者肺功能和呼吸动力学的影响[J].宁夏医科大学学报,2018,40(1):37-41.[22]李勇,何魏巍,王斐斐,等.无创正压通气联合沙丁胺醇及氨溴索治疗急性加重期慢性阻塞性肺疾病的临床效果观察[J].临床误诊误治,2020,33(6):28-32.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(16):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(16):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(16):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(16):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(16):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(16):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(16):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(16):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
[10]张善芳,汤 杰.穴位注射联合沙美特罗替卡松粉吸入剂治疗 慢性阻塞性肺疾病稳定期的临床疗效观察[J].医学信息,2018,31(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
　ZHANG Shan-fang,TANG Jie.Clinical Observation of Acupoint Injection Combined with Salmeterol and Fluticasone Powder Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
[11]汪晓琳,方 蕾,危 政.糖皮质激素、沙丁胺醇雾化吸入联合无创机械正压通气对COPD急性加重期患者血气指标及呼吸力学的影响[J].医学信息,2022,35(21):73.[doi:10.3969/j.issn.1006-1959.2022.21.016]
　WANG Xiao-lin,FANG Lei,WEI Zheng.Effect of Glucocorticoid and Salbutamol Atomization Inhalation Combined with Noninvasive Positive Pressure Ventilation on Blood Gas Index and Respiratory Mechanics in Patients with Acute Exacerbation of COPD[J].Journal of Medical Information,2022,35(16):73.[doi:10.3969/j.issn.1006-1959.2022.21.016]

更新日期/Last Update: 1900-01-01